BoccardoF., RubagottiA., AmorosoD.on behalf of the Italian Tamoxifen Arimidex (ITA) trial: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat, 82(Suppl 1): S6, abstract 3, 2003.
2.
BodyJ.J., DielI., LichinitserM.R.: Intravenous ibandronate reduce the incidence of skeletal complication in patients with breast cancer and bone metastases. Ann Oncol, 14: 1399–1405, 2003.
3.
BodyJ.J., DielI.J., BellR.: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 111: 306–312, 2004.
4.
BuzdarA.U.: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. Clin Breast Cancer, 5(Suppl 1), 2004.
5.
CazzanigaM.E., MustacchiG., DeMatteisA.: Adjuvant medical strategy and patterns of relapse in BC patients: the NORA project. Ann Oncol, 15(Suppl 2), abst A73, 2004.
6.
CoombesR.C., HallE., GibsonL.J.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 350: 1081–1092, 2004.
7.
EllisM.J., CoopA., SinghB.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol, 19: 3808–3816, 2001.
8.
GossP.E., IngleJ.N., MartinoS.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 349: 1793–1802, 2004.
9.
GreenJ.R., MullerK., JaeggiK.A.: Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res, 9: 745–751, 1994.
10.
LiptonA., TheriaultR.L., HortobagyiG.N.: Pamidronate prevents skeletal complication and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised placebo control trials. Cancer, 88: 1082–1090, 2000.
11.
MajorP., CookR.J., ChenB.L., ZhengM.: Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc ASCO, 22: 762 (abst 3062), 2003.
12.
OttavianiD., FerraciniR., FerreroG.: Osteo-on-cology multidisciplinary care group: a novel approach to the metastatic and primary bone tumor patient: the Molinette experience. Ann Oncol, 15(Suppl 2), abst D11, 2004.
13.
PavlakisN., StockierM.: Bisphosphonates for breast cancer. Cochrane Database Syst Rev., 2002 (1).
14.
RosenL.S., GordonD., TchekmedyianN.S.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer, 100: 2613–2621, 2004.
15.
ThomsenT., Banke-BochitaJ., HadjiP.: Effects of steroidal nonsteroidal aromatase inhibitors on markers of bone turnover and lipid metabolism in healthy volunteers. Breast Cancer Res Treat, 82(Suppl 1): S101, abst 427, 2003.
16.
TripathyD., BodyJ.J., DielI.: Oral daily ibandronate: efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer. Proc ASCO, 22: 46 (abst 185), 2003.
